β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men

Hideo Otsuki, Takeo Kosaka, Kenzo Nakamura, Junnji Mishima, Yoshitaka Kuwahara, Takuji Tsukamoto

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Purpose To investigate the safety and efficacy of mirabegron for patients with overactive bladder (OAB) that is unresponsive to antimuscarinic agents or is related to benign prostatic hyperplasia (BPH). Methods Fifty-two newly diagnosed OAB patients (M group) and 45 patients with OAB that was unresponsive to antimuscarinics (S group) received mirabegron 50 mg once daily and were evaluated by OAB symptom score (OABSS), IPSS-QOL index, and IPSS at the time of baseline, 4 and 8 weeks. Newly diagnosed OAB patients treated with antimuscarinic agents were compared as controls. Results Mirabegron was effective for 85.2 % in M group. Significant improvements were seen in each domain of OABSS, and there was no significant difference with antimuscarinic therapy. Mirabegron was efficacious for 61.6 % of S group, and significant decreases of OABSS and IPSS-QOL index were observed. Significant improvements were also seen in voiding symptoms in men. Post-void residual urine volumes before and after treatment were 32.1 and 34.8 ml, and 26.2 and 31.3 ml in M and S group, respectively, and there was no significant difference. The incidence of adverse events was 8.4 %, although none were serious, and the patients recovered spontaneously after mirabegron was discontinued. Conclusion The present study suggests mirabegron is as effective as antimuscarinics for OAB. It improves OAB symptoms in patients with OAB for which antimuscarinic agents are insufficient. This study revealed that mirabegron improves not only OAB symptoms related to BPH, but also voiding symptoms in men. Low and mild incidences of side effects support the safe utility of mirabegron.

Original languageEnglish
Pages (from-to)53-60
Number of pages8
JournalInternational Urology and Nephrology
Volume45
Issue number1
DOIs
Publication statusPublished - 2013 Feb

Fingerprint

Overactive Urinary Bladder
Muscarinic Antagonists
Prostatic Hyperplasia
Adrenergic Receptors
Therapeutics
mirabegron
Residual Volume
Incidence
Urine
Safety

Keywords

  • β3-Adrenoceptor
  • Antimuscarinics
  • Male OAB
  • Mirabegron
  • Overactive bladder

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. / Otsuki, Hideo; Kosaka, Takeo; Nakamura, Kenzo; Mishima, Junnji; Kuwahara, Yoshitaka; Tsukamoto, Takuji.

In: International Urology and Nephrology, Vol. 45, No. 1, 02.2013, p. 53-60.

Research output: Contribution to journalArticle

@article{c8cc7509e37b4c338e71481bcc0c06e3,
title = "β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men",
abstract = "Purpose To investigate the safety and efficacy of mirabegron for patients with overactive bladder (OAB) that is unresponsive to antimuscarinic agents or is related to benign prostatic hyperplasia (BPH). Methods Fifty-two newly diagnosed OAB patients (M group) and 45 patients with OAB that was unresponsive to antimuscarinics (S group) received mirabegron 50 mg once daily and were evaluated by OAB symptom score (OABSS), IPSS-QOL index, and IPSS at the time of baseline, 4 and 8 weeks. Newly diagnosed OAB patients treated with antimuscarinic agents were compared as controls. Results Mirabegron was effective for 85.2 {\%} in M group. Significant improvements were seen in each domain of OABSS, and there was no significant difference with antimuscarinic therapy. Mirabegron was efficacious for 61.6 {\%} of S group, and significant decreases of OABSS and IPSS-QOL index were observed. Significant improvements were also seen in voiding symptoms in men. Post-void residual urine volumes before and after treatment were 32.1 and 34.8 ml, and 26.2 and 31.3 ml in M and S group, respectively, and there was no significant difference. The incidence of adverse events was 8.4 {\%}, although none were serious, and the patients recovered spontaneously after mirabegron was discontinued. Conclusion The present study suggests mirabegron is as effective as antimuscarinics for OAB. It improves OAB symptoms in patients with OAB for which antimuscarinic agents are insufficient. This study revealed that mirabegron improves not only OAB symptoms related to BPH, but also voiding symptoms in men. Low and mild incidences of side effects support the safe utility of mirabegron.",
keywords = "β3-Adrenoceptor, Antimuscarinics, Male OAB, Mirabegron, Overactive bladder",
author = "Hideo Otsuki and Takeo Kosaka and Kenzo Nakamura and Junnji Mishima and Yoshitaka Kuwahara and Takuji Tsukamoto",
year = "2013",
month = "2",
doi = "10.1007/s11255-012-0343-5",
language = "English",
volume = "45",
pages = "53--60",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men

AU - Otsuki, Hideo

AU - Kosaka, Takeo

AU - Nakamura, Kenzo

AU - Mishima, Junnji

AU - Kuwahara, Yoshitaka

AU - Tsukamoto, Takuji

PY - 2013/2

Y1 - 2013/2

N2 - Purpose To investigate the safety and efficacy of mirabegron for patients with overactive bladder (OAB) that is unresponsive to antimuscarinic agents or is related to benign prostatic hyperplasia (BPH). Methods Fifty-two newly diagnosed OAB patients (M group) and 45 patients with OAB that was unresponsive to antimuscarinics (S group) received mirabegron 50 mg once daily and were evaluated by OAB symptom score (OABSS), IPSS-QOL index, and IPSS at the time of baseline, 4 and 8 weeks. Newly diagnosed OAB patients treated with antimuscarinic agents were compared as controls. Results Mirabegron was effective for 85.2 % in M group. Significant improvements were seen in each domain of OABSS, and there was no significant difference with antimuscarinic therapy. Mirabegron was efficacious for 61.6 % of S group, and significant decreases of OABSS and IPSS-QOL index were observed. Significant improvements were also seen in voiding symptoms in men. Post-void residual urine volumes before and after treatment were 32.1 and 34.8 ml, and 26.2 and 31.3 ml in M and S group, respectively, and there was no significant difference. The incidence of adverse events was 8.4 %, although none were serious, and the patients recovered spontaneously after mirabegron was discontinued. Conclusion The present study suggests mirabegron is as effective as antimuscarinics for OAB. It improves OAB symptoms in patients with OAB for which antimuscarinic agents are insufficient. This study revealed that mirabegron improves not only OAB symptoms related to BPH, but also voiding symptoms in men. Low and mild incidences of side effects support the safe utility of mirabegron.

AB - Purpose To investigate the safety and efficacy of mirabegron for patients with overactive bladder (OAB) that is unresponsive to antimuscarinic agents or is related to benign prostatic hyperplasia (BPH). Methods Fifty-two newly diagnosed OAB patients (M group) and 45 patients with OAB that was unresponsive to antimuscarinics (S group) received mirabegron 50 mg once daily and were evaluated by OAB symptom score (OABSS), IPSS-QOL index, and IPSS at the time of baseline, 4 and 8 weeks. Newly diagnosed OAB patients treated with antimuscarinic agents were compared as controls. Results Mirabegron was effective for 85.2 % in M group. Significant improvements were seen in each domain of OABSS, and there was no significant difference with antimuscarinic therapy. Mirabegron was efficacious for 61.6 % of S group, and significant decreases of OABSS and IPSS-QOL index were observed. Significant improvements were also seen in voiding symptoms in men. Post-void residual urine volumes before and after treatment were 32.1 and 34.8 ml, and 26.2 and 31.3 ml in M and S group, respectively, and there was no significant difference. The incidence of adverse events was 8.4 %, although none were serious, and the patients recovered spontaneously after mirabegron was discontinued. Conclusion The present study suggests mirabegron is as effective as antimuscarinics for OAB. It improves OAB symptoms in patients with OAB for which antimuscarinic agents are insufficient. This study revealed that mirabegron improves not only OAB symptoms related to BPH, but also voiding symptoms in men. Low and mild incidences of side effects support the safe utility of mirabegron.

KW - β3-Adrenoceptor

KW - Antimuscarinics

KW - Male OAB

KW - Mirabegron

KW - Overactive bladder

UR - http://www.scopus.com/inward/record.url?scp=84873408568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873408568&partnerID=8YFLogxK

U2 - 10.1007/s11255-012-0343-5

DO - 10.1007/s11255-012-0343-5

M3 - Article

VL - 45

SP - 53

EP - 60

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 1

ER -